Previous Article | Next Article ![]()
Journal of Clinical Microbiology, July 2000, p. 2525-2529, Vol. 38, No. 7
ID Biomedical Corp., Bothell, Washington
98011,1 and Mizuho USA Inc., San Diego,
California 921212
Received 23 November 1999/Returned for modification 31 January
2000/Accepted 5 April 2000
A Cycling Probe Technology (CPT) assay with a lateral-flow device
(strip) was developed for the detection of the mecA gene from methicillin-resistant Staphylococcus aureus (MRSA)
cultures. The assay uses a mecA probe (DNA-RNA-DNA) labeled
with fluorescein at the 5' terminus and biotin at the 3' terminus. The
CPT reaction occurs at a constant temperature, which allows the probe
to anneal to the target DNA. RNase H cuts the RNA portion of the probe, allowing the cleaved fragments to dissociate from the target DNA, making the target available for further cycling. The strip detection step uses a nitrocellulose membrane with streptavidin and
immunoglobulin G antibody impregnated on the surface. In the absence of
the mecA gene, the uncut probe is bound to an
antifluorescein-gold conjugate and is then captured by the streptavidin
to form a test line. In the presence of the mecA gene, the
probe is cut and no test line is formed on the strip. A screen of 324 S. aureus clinical isolates by the CPT-strip assay showed a
99.4% sensitivity and a 100% specificity compared to the results of
PCR for the detection of the mecA gene. Specificity testing
showed that the CPT-strip assay did not exhibit any cross-reactivity
with a panel of mecA-negative non-S. aureus
isolates. The CPT-strip assay is simple and does not require
sophisticated equipment. Furthermore, the assay takes 1.5 h
starting from a primary culture to the time to detection of the
mecA gene in S. aureus isolates.
The increased use of broad-spectrum
antibiotics in recent years has lead to the proliferation of
antibiotic-resistant strains of common bacteria. Methicillin-resistant
Staphylococcus aureus (MRSA) is an antibiotic-resistant
variant of S. aureus commonly found in hospitals around the
world. Since it was first reported, the prevalence of MRSA has
increased dramatically, with infections caused by MRSA becoming one of
the most commonly acquired types of nosocomial infections
(9). Thus, there is a need for rapid and efficacious methods
for the detection of MRSA.
Traditional methods of screening for MRSA use susceptibility tests that
are dependent on the phenotypic expression of resistance (6). However, these tests are time-consuming, requiring an initial culture period of 18 to 24 h followed by an additional 18 to 24 h for antibiotic susceptibility testing (16, 17). DNA-based assays for the detection of antibiotic resistance provide a
rapid method for the detection of MRSA (4). These assays test for the presence of genes that confer antibiotic resistance and
thus have an inherent time advantage over culture-based tests that
require phenotypic expression of the genes. Although PCR can detect the
mecA gene (1, 5, 15), the potential for cross
contamination, long turnaround times, and the expense and availability
of specialized equipment and trained staff may deter some laboratories
from using PCR for clinical diagnosis.
Cyclic Probe Technology (CPT) can be used to detect specific DNA
sequences (8). CPT is an isothermal reaction that is not prone to cross contamination because the target is not amplified. The
principle of CPT is outlined in Fig. 1a.
An excess of a chimeric DNA-RNA-DNA probe specifically hybridizes to
the target DNA in solution. RNase H cleaves the RNA portion of the
probe-target duplex, thus allowing the cut probe fragments to
dissociate from the target due to their lower melting temperatures. The
target is now free to hybridize with another intact probe molecule
while the cut probe fragments accumulate. With an isotopic detection format, CPT has been used for the detection of a tandem repeat DNA
sequence in Mycobacterium tuberculosis (2) and
has recently been successfully used for the detection of the
mecA gene in MRSA (7) and the vanA and
vanB genes in vancomycin-resistant enterococci (VRE)
(12).The mecA assay was modified to a nonisotopic
enzyme immunoassay (EIA) format that would be practical for use in
clinical laboratories where such a diagnostic kit would be most
valuable for the identification of MRSA (3). In the present
study, we describe a new format of the CPT assay in which a lateral
flow device (strip) is used to further simplify the procedure. The CPT-strip assay format significantly reduces the amount of hands-on manipulation by replacing the multistep, multireagent EIA detection step with a simple single-step procedure. The CPT-strip assay requires
90 min to process 24 samples after the initial culture, whereas the
CPT-EIA requires 2 h. The hands-on time of the CPT-strip assay is
approximately 25 to 30 min when processing 24 samples.
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Rapid Solid-Phase Immunoassay for Detection of
Methicillin-Resistant Staphylococcus aureus Using Cycling
Probe Technology
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (19K):
[in a new window]
FIG. 1.
Schematic diagram of CPT-strip assay used for the
detection of mecA in S. aureus cultures. (a) CPT.
A single-stranded target (I) serves as a template for CPT. In the
presence of probe (F-DNA-RNA-DNA-B) (II) and RNase H (III), the RNA
portion of the probe-target complex (IV) is cleaved by RNase H. The
shorter cleaved probe fragments dissociate from the target, thereby
regenerating the target DNA for further cycling (V). (b) Strip
detection. Upon placement of a strip into the CPT reaction, the probe
binds to Anti-F-GP and the complex of Anti-F-GP with uncut probe binds
to the streptavidin test line (VI). Excess Anti-F-GP binds to rabbit
anti-mouse IgG to form the control line (VII). A test line indicates
the presence of uncut probe and identifies the isolate in the sample as
MSSA, whereas the absence of a test line indicates that the probe was
cleaved and that the sample contains MRSA. The presence of the control
line confirms a normal flow of the liquid through the strip.
The strip is composed of four main components: (i) the sample pad, (ii)
the conjugate pad that contains mouse antifluorescein antibodies
conjugated to gold particles (Anti-F-GP), (iii) the nitrocellulose
membrane imprinted with a streptavidin line and an immunoglobulin G
(IgG) line, and (iv) an absorbent pad (Fig. 2). The CPT-strip assay uses the same
mecA chimeric probe labeled with fluorescein at the 5'
terminus and biotin at the 3' terminus as the EIA (3). When
the CPT reaction is finished, the strip is placed in the reaction tube
and the CPT reaction is absorbed into the sample pad and onto the
strip. The sample then flows through the conjugate pad where the
fluorescein of the chimeric probe binds to Anti-F-GPs. The complex of
uncut probe and Anti-F-GP, if present, will be captured by the
streptavidin via the probe's biotin and result in the development of a
"test" line. This test line indicates the absence of the
mecA target in the sample and identifies the isolate as a
methicillin-sensitive S. aureus (MSSA) isolate. Conversely,
the absence of a test line indicates an MRSA strain. A second line is
used as a control for the proper sample flow in the strip and develops
as the result of the binding of excess Anti-F-GP to the rabbit
anti-mouse IgG line. An outline of the CPT-strip format is shown in
Fig. 1.
|
To validate the CPT-strip assay, 324 clinical isolates of S. aureus were tested by the CPT-strip test. The assay was also tested for cross-reactivity against 19 mecA-negative non-S. aureus isolates. In addition, we tested the effect of growing a subset of the clinical isolates on three commonly used culture media prior to testing by the CPT-strip assay.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Bacterial strains. Reference strains of MSSA (ATCC 29213) and MRSA (ATCC 33592) were used as negative and positive controls, respectively, for the assay. Clinical isolates of staphylococci used in the blind screen were obtained from Cleveland Clinic Foundation (Cleveland, Ohio), Wishard Memorial Hospital (Indianapolis, Ind.), Hospital of the University of Pennsylvania (Philadelphia, Pa.), Primary Children's Medical Center (Salt Lake City, Utah), Sunnybrook Health Science Centre (North York, Ontario, Canada), Veterans Affairs Medical Center (Nashville, Tenn.), University of Alabama (Birmingham, Ala.), and Vancouver General Hospital (Vancouver, British Columbia, Canada). A total of 324 S. aureus isolates, including 6 borderline-resistant S. aureus strains, were tested. As well, 12 non-S. aureus staphylococcal organisms from the American Type Culture Collection (ATCC; S. capitis ATCC 35661), S. cohnii ATCC 35662, S. epidermidis ATCC 14990, S. haemolyticus ATCC 29970, S. hominis ATCC 27844, S. lugdunensis ATCC 43809, S. saprophyticus ATCC 15305, S. sciuri ATCC 29060, S. schleiferi ATCC 43808, S. simulans ATCC 27851, S. warneri ATCC 27836, and S. xylosus ATCC 29971, and 7 nonstaphylcoccal organisms from ATCC (Candida albicans ATCC 10231, Enterococcus faecalis ATCC 29212, Enterococcus faecium ATCC 51299, Escherichia coli ATCC 25922, Lactobacillus lactis ATCC 19435, Leuconostoc mesenteroides ATCC 8293-1, and Klebsiella pneumoniae ATCC 13883) were tested to determine the cross-reactivity of the CPT-strip assay.
Sample preparation. The strains were grown overnight (18- to 24-h culture) at 37°C on tryptic soy agar (TSA) with 5% sheep blood (PML Microbiologicals, Wilsonville, Oreg.). Other media tested were mannitol-salt agar and Columbia agar with 5% horse blood (all from PML Microbiologicals), and these media were used in the same overnight culture procedure with 96 of the clinical isolates chosen at random. Samples were prepared by using a 1-µl BAC-LOOP inoculation loop (PML Microbiologicals) to suspend one loopful of cells in 50 µl of lysis reagent in a 1.8-ml capless microcentrifuge tube (Evergreen Scientific, Los Angeles, Calif.). The composition of the lysis reagent was 20 mM TES [N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid; pH 8.2], 0.05% Triton X-100, 100 µM EGTA, 200 U of achromopeptidase (Wako Bioproducts, Richmond, Va.) per ml, 100 mM trehalose, and the preservative ProClin 300 (Supelco Park, Belefonte, Pa.) at 20 ppm. Achromopeptidase is a bacteriolytic hydrolase enzyme that lyses the bacterial cell wall. Cell suspensions were lysed by incubation for 20 min in a 55°C heating block (Barnstead Thermolyne, Dubuque, Iowa).
CPT-strip assay. (i) CPT. The contents of microcentrifuge tubes that contained 50 µl of crude lysate were allowed to denature in a heating block (Barnstead Thermolyne) for 5 min (to achieve an in-tube temperature of 96 ± 1°C) and were then transferred back to the 55°C heating block. A 50-µl aliquot of cycling reagent was added to each tube. The 100-µl reaction mixture contained 20 mM TES (pH 7.2), 0.05% Triton X-100, 2 mM MgCl2, 0.625 mM spermine tetrahydrochloride, 100 mM trehalose, 0.1% polyvinylpyrrolidone, 2 µg of bovine serum albumin per ml, 10 fmol of F-mecA945-29-B probe, and 1.0 µg of RNase H. RNase H and the mecA probe were as described elsewhere (3). Cycling reactions were incubated for 25 min in the 55°C heating block.
(ii) Strip detection step.
After the 25-min incubation, one
4-mm-wide strip (Mizuho USA, San Diego, Calif.) was placed into each
reaction tube at 55°C, and the tube was immediately removed from the
heating block and placed at room temperature. The strips were kept in
the reaction tube for 15 min at room temperature to allow sample flow,
and then the strips were observed for the presence of a control line and a test line. The presence of a control line indicated a normal flow
of the liquid through the strip; if the control line was not present,
the test was considered invalid and the assay was repeated. The
interpretation of results is summarized in Table 1.
|
PCR. The presence or absence of the mecA gene was determined by PCR as described previously (7). Briefly, 30 PCR cycles were used to amplify a 227-bp fragment with the following primers: mecA834-25 (5'-TGGTAAAAAGGGACTCGAAAAACTT-3') and mecAL1039-22 (5'-GGTGGATAGCAGTACCTGAGCC-3'). The amplified DNA was resolved on a 1.5% agarose gel with 5 µl of the 100-µl PCR mixture. The gel was stained with Sybr Green I dye (Molecular Probes, Eugene, Oreg.) and was scanned with a FluoroImager (Molecular Dynamics, Sunnyvale, Calif.).
| |
RESULTS |
|---|
|
|
|---|
Screens of clinical isolates.
The 324 staphylococcal isolates
were analyzed by PCR. A single 227-bp band was observed with 174 isolates; these isolates were designated mecA positive. No
band was observed with 150 isolates; these isolates were designated
mecA negative (data not shown). A screen of the 324 staphylococcal isolates was performed by the CPT-strip assay. The ATCC
reference strains were tested in parallel as positive and negative
controls. The results of the screen are as follows: 173 isolates were
CPT-strip assay positive and PCR positive, 150 isolates were CPT-strip
assay negative and PCR negative, and 1 isolate was CPT-strip
assay negative and PCR positive. No isolate was CPT-strip assay
positive and PCR negative. All samples showed a control line on the
strips as expected. An example of a strip used with a sample that
contained MSSA (presence of a test line) and a strip used with a sample
that contained MRSA (no test line) is shown in Fig.
3.
|
Cross-reactivity testing of CPT-strip assay. Twelve non-S. aureus isolates and seven nonstaphylococcal clinical isolates tested by the CPT-strip test showed no cross-reactivity with the mecA probe. As expected, all of these samples showed test lines, indicating the absence of the mecA gene. However, testing of methicillin-resistant S. epidermidis (MRSE) did not consistently identify the presence of the mecA gene (data not shown).
Testing of alternate media for cell culture.
A subset of the
S. aureus clinical isolates from the previous screen were
plated onto two media commonly used in clinical microbiology
laboratories as alternatives to TSA with 5% sheep blood. The two new
media tested gave results comparable to those obtained with TSA with
sheep blood. The results are summarized in Table
2.
|
| |
DISCUSSION |
|---|
|
|
|---|
The CPT-strip assay described in this paper accurately determined the presence or absence of the mecA gene. The results of a blind screen of 324 S. aureus isolates showed 99.4% sensitivity and 100% specificity compared to the results of PCR. Furthermore, the CPT-strip assay has several key advantages over PCR-based methods for the detection of the mecA gene. First, the CPT-strip assay is simple and thus requires very little training and hands-on manipulation. Second, it does not require specialized equipment such as a thermal cycler, and the results are read visually with no need to run a gel. Finally, there is no risk of carryover contamination as with PCR since the target is not amplified.
Since the CPT-strip assay tests for the presence of the mecA gene, it is an improvement over the traditional culture-based susceptibility tests used in clinical microbiology laboratories. The CPT-strip assay significantly reduces the time required to detect MRSA compared to the time to detection by susceptibility testing. Furthermore, borderline-resistant S. aureus strains that lack the mecA gene but that are often mischaracterized by susceptibility testing (11, 13, 14) are correctly identified as mecA negative by the CPT-strip assay.
All 150 mecA-negative isolates were correctly identified in the blind screen by the CPT-strip assay. Furthermore, 173 of 174 mecA-positive isolates were correctly identified. The false-negative isolate was characterized as MRSA by oxacillin agar screening (data not shown). This isolate was observed to be difficult to suspend during sample preparation for lysis due to its tendency to stick to the inoculation loop and form clumps. Thus, most likely, the isolate was not lysed sufficiently to release enough DNA for the CPT reaction to efficiently cleave the chimeric probe. Increasing the CPT time has been shown to improve the efficiency of probe cleavage when there are low levels of target DNA (data not shown). In this case, though, increasing the CPT time did not solve the problem with the sticky isolate. However, difficult-to-suspend isolates are rare; i.e., only 1 such isolate was identified among a total of 324 S. aureus isolates tested, an incidence rate of less than 1%. Further investigation is required to solve the problem of sticky isolates. For example, changing the lysis methods by including another lytic enzyme or a detergent or using a bead beating step may improve the suspension of the sticky isolates.
The CPT-strip assay also showed no cross-reactivity with mecA-negative strains: 12 non-S. aureus isolates and 7 nonstaphylococcal isolates. Our assay is recommended for use with presumptively identified S. aureus isolates. Normally, non-S. aureus isolates would be screened out by primary culture and coagulase testing; however, strains are occasionally mischaracterized and the CPT-strip test may be used with these organisms. Our results confirm that such strains will not be further misidentified as mecA-positive strains.
We recommend TSA with 5% sheep blood as the culture medium for use with the CPT-strip assay. However, some clinical laboratories may routinely use other types of media for primary culture. Therefore, we tested two other commonly used media in combination with the CPT-strip assay. Mannitol-salt agar and Columbia agar with 5% horse blood were shown to perform comparably to TSA with 5% sheep blood. Thus, it would likely not be necessary for most clinical microbiology laboratories to alter their normal primary culture method to successfully run the CPT-strip assay.
There are, however, some limitations to the technique described here. Studies on detection of the mecA gene in MRSE by the CPT-strip assay did not consistently identify the presence of the mecA gene. Since the mecA sequence is homologous in MRSA and MRSE (15, 18), we would expect that the CPT-strip assay should detect the target sequence. The most likely reason for the failure to identify MRSE is insufficient lysis of the S. epidermidis cells. Thus, the assay could be modified to improve the lysis of S. epidermidis.
We have shown that the CPT-strip assay is a rapid, simple, and accurate new method for the detection of MRSA. Previous studies have used gene-based systems for detection of the mecA gene. For example, a DNA hybridization assay with chemiluminescence detection has been developed (10). This assay requires a luminometer and takes 3.5 h to process 25 samples after isolation by culture. Alternatively, the enzymatic detection of PCR products from colonies of clinical isolates can be completed within 3 h (18). More recently, a branched-DNA assay based on probe signal amplification was shown to accurately detect the mecA gene in MRSA and coagulase-negative staphylococci. The branched-DNA assay uses a luminometer during the detection step and takes 6 h to complete (11). By comparison, after an initial 24-h culture, the CPT-strip assay described here would require 1.5 h to discriminate between mecA-positive and mecA-negative strains for 24 S. aureus isolates. Because the CPT-strip assay is rapid and the results are determined visually, we expect that the CPT-strip assay will be a valuable tool for the rapid detection of methicillin resistance in clinical staphylococci as well as for other gene-based detection systems.
| |
ACKNOWLEDGMENTS |
|---|
We thank Julie Johnston, Dondi Flanagan, Nancy Parsons, Glenna Peterson, Alfred Wong, Helen Balzer, and Alka Patel for technical assistance. We also thank Robert Bryan and Roger Lankford for helpful suggestions and Lynn Cloney for critical review of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: Saskatchewan Research Council, Genetics Branch, 15 Innovation Blvd., Saskatoon, Canada S7N 2X8. Phone: (306) 933-5448. Fax: (306) 933-5505. E-mail: bekkaoui{at}src.sk.ca.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Barski, P., L. Piechowicz, J. Galinski, and J. Kur. 1996. Rapid assay for detection of methicillin-resistant Staphylococcus aureus using multiplex PCR. Mol. Cell Probes 10:471-475[CrossRef][Medline]. |
| 2. | Beggs, M. L., M. D. Cave, C. Marlowe, L. Cloney, P. Duck, and K. D. Eisenach. 1996. Characterization of Mycobacterium tuberculosis complex direct repeat sequence for use in cycling probe reaction. J. Clin. Microbiol. 34:2985-2989[Abstract]. |
| 3. | Bekkaoui, F., J. P. McNevin, C. H. Leung, G. J. Peterson, A. Patel, R. S. Bhatt, and R. N. Bryan. 1999. Rapid detection of the mecA gene in methicillin resistant staphylococci using a colorimetric cycling probe technology. Diagn. Microbiol. Infect. Dis. 34:83-90[CrossRef][Medline]. |
| 4. |
Bergeron, M. G., and M. Ouellette.
1998.
Preventing antibiotic resistance through rapid genotypic identification of bacteria and of their antibiotic resistance genes in the clinical microbiology laboratory.
J. Clin. Microbiol.
36:2169-2172 |
| 5. |
Bignardi, G. E.,
N. Woodford,
A. Chapman,
A. P. Johnson, and D. C. Speller.
1996.
Detection of the mec-A gene and phenotypic detection of resistance in Staphylococcus aureus isolates with borderline or low-level methicillin resistance.
J. Antimicrob. Chemother.
37:53-63 |
| 6. | Chambers, H. F. 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10:781-791[Abstract]. |
| 7. | Cloney, L., C. Marlowe, A. Wong, R. Chow, and R. Bryan. 1999. Rapid detection of mecA in methicillin resistant Staphylococcus aureus using cycling probe technology. Mol. Cell Probes 13:191-197[CrossRef][Medline]. |
| 8. | Duck, P., G. Alvarado-Urbina, B. Burdick, and B. Collier. 1990. Probe amplifier system based on chimeric cycling oligonucleotides. BioTechniques 9:142-148[Medline]. |
| 9. | Jacoby, G. A. 1996. Antimicrobial-resistant pathogens in the 1990s. Annu. Rev. Med. 47:169-179[CrossRef][Medline]. |
| 10. | Kolbert, C. P., J. E. Connolly, M. J. Lee, and D. H. Persing. 1995. Detection of the staphylococcal mecA gene by chemiluminescent DNA hybridization. J. Clin. Microbiol. 33:2179-2182[Abstract]. |
| 11. |
Kolbert, C. P.,
J. Arruda,
P. Varga-Delmore,
X. Zheng,
M. Lewis,
J. Kolbert, and D. H. Persing.
1998.
Branched-DNA assay for detection of the mecA gene in oxacillin-resistant and oxicillin-sensitive staphylococci.
J. Clin. Microbiol.
36:2640-2644 |
| 12. | Modrusan, Z., C. Marlowe, D. Wheeler, M. Pirseyedi, and R. N. Bryan. 1999. Detection of vancomycin resistant genes vanA and vanB by cycling probe technology. Mol. Cell Probes 13:223-231[CrossRef][Medline]. |
| 13. | Montanari, M. P., O. Massidda, M. Mingoia, and P. E. Varaldo. 1996. Borderline susceptibility to methicillin in Staphylococcus aureus: a new mechanism of resistance? Microb. Drug Resist. 2:257-260[Medline]. |
| 14. | Mulligan, M. E., K. A. Murray-Leisure, B. S. Ribner, H. C. Standiford, J. F. John, J. A. Korvick, C. A. Kauffman, and V. L. Yu. 1993. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am. J. Med. 94:313-328[CrossRef][Medline]. |
| 15. |
Murakami, K.,
W. Minamide,
K. Wada,
E. Nakamura,
H. Teraoka, and S. Watanabe.
1991.
Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction.
J. Clin. Microbiol.
29:2240-2244 |
| 16. | National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 5th ed. Document M7-A5. National Committee for Clinical Laboratory Standards document Wayne, Pa. |
| 17. |
Petersson, A. C.,
H. Miorner, and C. Kamme.
1996.
Identification of mecA-related oxacillin resistance in staphylococci by the E test and the broth microdilution method.
J. Antimicrob. Chemother.
37:445-456 |
| 18. |
Ubukata, K.,
S. Nakagami,
A. Nitta,
A. Yamane,
S. Kawakami,
M. Sugiura, and M. Konno.
1992.
Rapid detection of the mecA gene in methicillin-resistant staphylococci by enzymatic detection of polymerase chain reaction products.
J. Clin. Microbiol.
30:1728-1733 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»